Filing for Chapter 11 protection typically indicates financial distress, which can lead to a loss of investor confidence and a decrease in stock price. Given that Eiger BioPharmaceuticals has directly filed for bankruptcy, this is a significant event that directly impacts its financial stability and future operations, leading to a negative perception among investors and a likely decrease in stock value in the short term.